Insulet Corporation — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Insulet develops and sells the Omnipod tubeless insulin-delivery system and supplies drug-delivery products, including pods used in Amgen’s Neulasta Onpro kit. Amounts below are in U.S. dollars.
Financial performance
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $263.2 million | $226.3 million | $515.5 million | $424.3 million |
| Gross profit / margin | $182.7 million / 69.4% | $142.5 million / 63.0% | $350.2 million / 67.9% | $269.4 million / 63.5% |
| Operating income | $26.3 million | $27.5 million | $42.6 million | $35.0 million |
| Net income (loss) | $(25.0) million | $14.4 million | $(25.0) million | $12.3 million |
| Adjusted EBITDA (non-GAAP) | $52.3 million | $44.2 million | $87.4 million | $68.5 million |
- Q2 revenue increased 16.3% reported and 12.5% at constant currency; six-month revenue increased 21.5% and 17.8%, respectively. Omnipod drove growth: Q2 U.S. revenue rose 16.8% and international revenue 25.1% reported (13.4% constant currency). Q2 Drug Delivery revenue fell 13.2% to $21.1 million; six-month revenue rose 23.3% to $40.2 million.
- Q2 gross margin expanded 640 basis points, attributed primarily to manufacturing and supply-chain efficiencies, favorable currency, lower COVID-related costs, and pharmacy-channel mix, partly offset by higher costs from scaling U.S. manufacturing. SG&A rose 43.9% in Q2 to $116.3 million, reflecting added personnel, advertising, and commercial investment; R&D rose 17.3% to $40.1 million.
- Q2 net loss included a $40.1 million loss on extinguishment of debt and $16.4 million net interest expense. Six-month operating cash flow was negative $16.8 million, versus positive $22.8 million a year earlier; the company cited a $104.2 million working-capital outflow, including inventory build and increases in receivables and prepaid/other assets. Capital expenditures were $52.8 million.
Financial position and debt
- At June 30, 2021, cash and cash equivalents were $854.6 million and short-term investments were $17.5 million. Total current assets were $1,252.9 million and current liabilities $213.3 million.
- Total debt was $1,256.1 million, including $20.9 million current and $1,235.2 million long-term; the filing reports these balance-sheet amounts net of discounts and issuance costs. The company had $832.1 million principal outstanding in convertible notes and a $500 million term loan. No borrowings were outstanding on its $60 million revolving facility.
- In May, Insulet borrowed $500 million under a seven-year secured term loan and used proceeds, together with cash and 2.2 million shares issued, to repurchase part of its 1.375% convertible notes. It paid $460.8 million cash and issued shares valued at $622.7 million in the transaction. Swaps fixed the rate on 96% of the term loan exposure at 4.20% through April 2025. Management said available liquidity should cover projected operating, investing, and debt-service needs for at least 12 months.
Outlook, risks, and notable items
- Management expected 2021 gross margin of 68%–69%, strong U.S. Omnipod growth, and higher international Omnipod revenue; Drug Delivery revenue was expected to decline or grow slightly. R&D, SG&A, and capital spending were expected to increase year over year.
- FDA review of Omnipod 5 was taking longer than anticipated. The company expected clearance and a limited commercial release in the second half of 2021, most likely late Q4, and said the timing shift was not expected to materially affect 2021 revenue. The preschool indication was planned for 2022, dependent on clearance; the company had completed enrollment in a Type 2 feasibility study.
- Key risks include reliance on Omnipod, manufacturing capacity and supply-chain constraints, reimbursement and competition, product and regulatory risks, international expansion, cybersecurity, and the ability to service debt. The filing identifies a U.S. patent lawsuit brought by Roche seeking monetary damages; Insulet said it could not estimate potential losses, which could be material. A U.K. patent case brought by Insulet ended in Roche’s favor, with no injunction or damages.
- Two customers together represented 26% of Q2 and six-month revenue. A distribution agreement with a distributor whose executive is the spouse of a director generated $3.3 million Q2 revenue; the company said its terms were arm’s-length. In July, $20 million principal of convertible notes converted into approximately 215,000 shares, and Insulet entered into $43.1 million of equipment financing.
Investor verification points
- Track Omnipod 5 FDA clearance and launch timing, and confirm the resulting 2021 revenue and margin impact.
- Assess the durability of gross-margin improvement against manufacturing scale-up costs and rising SG&A, R&D, and capital investment.
- Monitor operating cash conversion, inventory growth, and working-capital requirements alongside the 2021 capacity expansion.
- Review debt service, covenant terms, interest-rate exposure, subsequent note conversions, and dilution from share issuance.
- Follow the Roche U.S. litigation, customer concentration, and the related-party distributor relationship.